Taysha Gene Therapies, Inc. (TSHA)
NASDAQ · Manufacturing · Biological products, (no diagnostic substances)
TSHA price, last 12 months
Key stats
- Previous close
- $3.99
- Open
- $4.01
- Day range
- $3.75 – $4.13
- 52-week range
- $3.46 – $7.30
- Volume
- 2.2M
- Avg volume (20 days)
- 2.8M
- Market cap
- $1.3B
Performance
Technicals and fundamentals
About Taysha Gene Therapies, Inc.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.
- Sector
- Manufacturing
- Industry
- Biological products, (no diagnostic substances)
- Listed on
- NASDAQ
- Market cap
- $1.3B